Suven Life secures three more patents

The patents have been granted to new chemical entities for treatmentof Alzheimers' and Parkinson's

Hyderabad-based biopharmaceutical company Suven Life Sciences Limited has secured two product patents from Canada and one  product patent from Eurasia corresponding to the new chemical entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases. These patents are valid through 2028.

The granted patents include the class of selective 5-HT compounds discovered by the company and are being developed as therapeutic agents useful in the treatment of cognitive impairment associated with Alzheimer’s disease, attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinson and Schizophrenia.

With the these patents, Suven now has a total  of  12 patents from Canada and 13 from Eurasia. These patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts.

Products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II, the company stated in a press release on Friday.